Loading...
Docoh

VBI Vaccines (VBIV)

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Company profile

Ticker
VBIV
Exchange
CEO
Jeffrey R. Baxter
Employees
Location
Fiscal year end
Former names
LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.
SEC CIK
Subsidiaries
VBI Vaccines (Delaware) Inc. • SciVac Ltd. • Variation Biotechnologies (US), Inc. • Variation Biotechnologies Inc. • SciVac Hong Kong Limited ...

VBIV stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

9 May 22
26 Jun 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 101.34M 101.34M 101.34M 101.34M 101.34M 101.34M
Cash burn (monthly) 6.79M 574.08K 7.08M 6.29M 6.64M 4.43M
Cash used (since last report) 19.47M 1.65M 20.33M 18.04M 19.06M 12.72M
Cash remaining 81.87M 99.69M 81.01M 83.3M 82.28M 88.62M
Runway (months of cash) 12.1 173.7 11.4 13.2 12.4 20.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Jan 22 Anderson David Evander Option (Right to Buy Common Shares) Common Shares Grant Acquire A No No 1.53 400,000 612K 400,000
27 Jan 22 Bain Linda Option (Right to Buy Common Shares) Common Shares Grant Acquire A No No 1.53 75,000 114.75K 75,000
27 Jan 22 Baxter Jeff Option (Right to Buy Common Shares) Common Shares Grant Acquire A No No 1.53 800,000 1.22M 800,000
27 Jan 22 Beattie Nell Option (Right to Buy Common Shares) Common Shares Grant Acquire A No No 1.53 400,000 612K 400,000
27 Jan 22 Damian Braga Option (Right to Buy Common Shares) Common Shares Grant Acquire A No No 1.53 75,000 114.75K 75,000
44.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 129 135 -4.4%
Opened positions 15 21 -28.6%
Closed positions 21 11 +90.9%
Increased positions 46 47 -2.1%
Reduced positions 35 39 -10.3%
13F shares Current Prev Q Change
Total value 191.15M 351.73M -45.7%
Total shares 115.36M 111.33M +3.6%
Total puts 195.4K 544.7K -64.1%
Total calls 260.5K 393.9K -33.9%
Total put/call ratio 0.8 1.4 -45.8%
Largest owners Shares Value Change
Perceptive Advisors 52.34M $86.88M 0.0%
STT State Street 16.22M $26.92M +31.1%
BLK Blackrock 13.22M $21.95M -0.4%
Vanguard 5.07M $8.42M -0.2%
Geode Capital Management 3.93M $6.52M +4.2%
Cambridge Investment Research Advisors 2.19M $3.64M +2.0%
NTRS Northern Trust 1.89M $3.14M -4.9%
GAM General American Investors 1.88M $3.12M 0.0%
Charles Schwab Investment Management 1.64M $2.73M +2.7%
Rafferty Asset Management 1.09M $1.82M +29.3%
Largest transactions Shares Bought/sold Change
STT State Street 16.22M +3.84M +31.1%
Millennium Management 571.36K -1.17M -67.2%
Susquehanna International 414.72K -829.93K -66.7%
MS Morgan Stanley 980.66K +744.05K +314.5%
Frontier Wealth Management 601.8K +565.8K +1571.7%
C Citigroup 176.38K -475.43K -72.9%
BAC Bank Of America 809.43K +380.84K +88.9%
UBS UBS Group AG - Registered Shares 1.03M +322.96K +45.5%
Rafferty Asset Management 1.09M +248.27K +29.3%
Group One Trading 98.61K -245.31K -71.3%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: ACIP, acute, Additionally, adjusted, adjustment, adsorbed, adult, ancestral, animal, Area, asymptomatic, bat, begun, benchmarked, bifurcated, bite, brain, Brazil, burden, CDC, cGMP, chemotherapy, childbirth, CHMP, cold, Combo, conclusion, conflict, contemplated, decade, difficult, distant, divergent, drawn, East, EC, ECDRP, EEA, EU, exhibit, field, Floor, formal, geopolitical, Gilbert, Iceland, inclusion, India, inflammation, inhibitor, injury, instrument, interferon, internationally, joined, joint, knowledge, Lambda, Liechtenstein, longer, low, macroeconomic, main, malignant, median, Medicinal, member, mice, Middle, mild, month, mortality, mosquito, move, neurological, newly, North, Norway, nrtl, Omicron, outbreak, overview, passed, pathogenic, PB, pegylated, persistently, PNA, pregnancy, PreHevbri, PreHevbrio, PRNT, Procedure, pseudoparticle, radiation, recommendation, recommended, reimbursed, resection, respiratory, reverse, ROU, Russia, seasoned, sexually, silent, stronger, subvariant, summer, surgical, sustain, Syndrome, therapy, title, today, topline, transcriptase, transmitted, turn, typically, Ukraine, unanimously, unaware, underway, universally, VOC, voted, week, Zika
Removed: abandon, AgreementSM, Application, approve, awarded, BLA, block, BMI, boost, broadly, capacity, certificate, certification, CHO, closed, Coalition, comply, consecutive, consistency, consistent, CONSTANT, deep, demonstrating, diabetic, diminish, directly, distinguished, divided, Epidemic, equipment, exclusively, expression, Fee, GMP, governed, granting, guarantee, hepatocellular, III, immunological, IMoH, indirectly, inhibit, leading, load, LP, mammalian, modernization, modernized, multiplied, obligated, PDUFA, Perceptive, pivotal, practice, Prescription, problem, PROTECT, reactive, recently, receptor, Region, remained, remove, restoration, robust, sensitive, seroprotection, simplify, size, Society, sponsor, SPR, subgroup, submitted, superiority, temporarily, transmissibility, understanding, uniquely, unknown, User, validation, vary, yeast